-
公开(公告)号:US12121688B2
公开(公告)日:2024-10-22
申请号:US17426848
申请日:2020-01-31
申请人: Novo Nordisk A/S
CPC分类号: A61M37/0069 , A61M31/002 , A61M2210/1053 , A61M2210/106 , A61M2210/1064
摘要: A medical delivery device suitable for insertion into a lumen of a patient, the medical device (100, 200) comprising a capsule (110, 120, 210, 220) sized to be inserted into the lumen, the capsule comprising a base member, and an actuation mechanism comprising an actuation member (150, 250, 350) configured for movement relative to the base member along an axis, and an energy source (140, 240, 340) associated with the actuation member for powering the actuation member to move relative to the base member along the axis. The base member and the actuation member define a latch assembly comprising: a) a dissolvable firing member (160, 260, 360), the dissolvable firing member being at least partially dissolvable when subjected to a biological fluid, b) a retainer portion (113, 213, 313) comprised by one of the base member and the actuation member, and c) a movable latch (152, 252, 352) configured for lateral movement relative to the axis, the movable latch defining a first surface with a blocking portion (153, 253, 353), and a second surface (152a, 252a, 352a) configured for interacting with the dissolvable firing member (160, 260, 360). In a pre-firing configuration, the blocking portion (153, 253, 353) of the movable latch engages the retainer portion (113, 213, 313) in a latching engagement, and the second surface (152a, 252a, 352a) of the movable latch interacts with the dissolvable firing member to restrict lateral movement of the movable latch thereby preventing release of the latching engagement. In a firing configuration where the dissolvable firing member (160, 260) has become at least partially dissolved, the movable latch is allowed to move laterally thereby releasing the latching engagement.
-
公开(公告)号:US12115358B2
公开(公告)日:2024-10-15
申请号:US16981328
申请日:2019-03-22
申请人: Novo Nordisk A/S
CPC分类号: A61M5/31595 , A61M5/2033 , A61M5/31526 , A61M5/3202 , A61M2005/3126
摘要: A drug delivery device includes a dose counting mechanism and an end-of-content or remaining-dose indication. For example, a dose expelling mechanism is coupled to a reciprocating element configured to undergo a predefined motion during each dose expelling action to allow a dose to be expelled. The predefined motion includes displacement in a first axial direction from a first position to a second position followed by displacement in a second axial direction from the second position to the first position, with a counter element being movable in the first axial direction. First and second unidirectional ratchet mechanisms prevent motion in the first axial direction and allow motion in the second axial direction of the reciprocating element relative to the counter element, and vice versa, respectively.
-
公开(公告)号:US12084512B2
公开(公告)日:2024-09-10
申请号:US16481108
申请日:2018-02-01
申请人: Novo Nordisk A/S
发明人: Karina Thorn , Bjarne Gram Hansen , Laust Bruun Johnsen , Mikkel Nors Harndahl , Zhiru Yang , Henrik Oestergaard , Per J. Greisen , Morten Groenbech Rasch , Jianhe Chen , Haisun Zhu , Rong Zhou , Prafull S. Gandhi
CPC分类号: C07K16/36 , A61K39/001154 , A61P7/04 , A61K2039/505 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/75 , C07K2317/92
摘要: The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.
-
公开(公告)号:US20240252796A1
公开(公告)日:2024-08-01
申请号:US18566555
申请日:2022-06-09
申请人: Novo Nordisk A/S
IPC分类号: A61M31/00
CPC分类号: A61M31/002
摘要: A self-righting ingestible capsule comprising: a) a capsule housing (110, 120) defining a central axis and having proximal and distal ends, b) a sealing compartment (A) within the capsule housing (110, 120) accommodating a solid dose member (130), and comprising a distal exit port (124), c) an actuation compartment (B) fluidically isolated from the scaling compartment (A), d) an actuation member (150) at least partially accommodated in the actuation compartment (B) and arranged for axial displacement thereby moving the dose member (130) distally through the distal exit port (124), e) a helical spring (140) for powering the actuation member (150) in a distal direction, f) a latch component (152) coupled to the actuation member (150) for releasably maintaining the actuation member latched in a proximal position, and g) a dissolvable latch support (160) disposed in the actuation compartment (B), wherein the dissolvable latch support maintains latching of the actuation member (150) in the proximal position by supporting the latch component
-
公开(公告)号:US20240242810A1
公开(公告)日:2024-07-18
申请号:US18289294
申请日:2022-05-05
申请人: Novo Nordisk A/S
IPC分类号: G16H20/17
CPC分类号: G16H20/17
摘要: A method of estimating insulin on board (IOB) for a given glucose sensitive insulin (GSI) in a subject is provided. The method comprises the steps (i) for the given GSI, providing at least one rate constant (rc) as function of glucose concentration (rc(G)), (ii) providing for a period of time a continuous blood glucose log G(t) from the subject, (iii) providing for the period of time 5 an insulin dose log I(t) from the subject, (iv) based on rc(G) and G(t), calculating for each rc a rate constant as function of time (rc(t)), and (v) based on the at least one rc(t) and I(t) and using an estimating algorithm, calculating an estimated IOB for the subject.
-
公开(公告)号:US12029779B2
公开(公告)日:2024-07-09
申请号:US16844552
申请日:2020-04-09
申请人: Novo Nordisk A/S
发明人: Marianne Oelholm Larsen Groenning , Lars Endahl , Charlotte Giwercman Carson , Anders Bjerring Strathe , Maria Kabisch , Thomas Hansen
CPC分类号: A61K38/26 , A61P3/04 , A61K9/0019
摘要: The present invention relates to semaglutide for use in weight management.
-
公开(公告)号:US12024542B2
公开(公告)日:2024-07-02
申请号:US17687755
申请日:2022-03-07
申请人: Novo Nordisk A/S
发明人: Per Noergaard
IPC分类号: C07K14/395 , C07K14/605 , C12P21/02
CPC分类号: C07K14/395 , C07K14/605 , C12P21/02 , C07K2319/00
摘要: The present invention is related to Mating Factor α pro-peptide variants useful for the recombinant expression of polypeptides comprising a GLP-1 peptide in yeasts. The invention is also related to DNA sequences, vectors and host cells for use in expressing polypeptides in yeasts.
-
公开(公告)号:US20240207364A1
公开(公告)日:2024-06-27
申请号:US18426412
申请日:2024-01-30
申请人: Novo Nordisk A/S
CPC分类号: A61K38/26 , A61K9/2013 , A61P25/28
摘要: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.
-
9.
公开(公告)号:US20240206458A1
公开(公告)日:2024-06-27
申请号:US18576859
申请日:2022-07-12
申请人: Novo Nordisk A/S
IPC分类号: A01N1/02
CPC分类号: A01N1/0284 , A01N1/0252
摘要: The present invention relates to a method for establishing a cell bank, comprising the steps of providing a batch of cell suspension comprising stem cells or stem cell-derived cells, and a cryopreservation medium, maintaining the batch of cell suspension at a temperature below 15° C., and transferring an amount of the cell suspension from the batch of cell suspension into one or more storage containers, wherein establishing the cell bank takes at least (30) minutes.
-
公开(公告)号:US20240199533A1
公开(公告)日:2024-06-20
申请号:US18274614
申请日:2022-01-28
申请人: Novo Nordisk A/S
发明人: Niels Krogsgaard-Larsen , Michael Raunkjaer , Christian Walter Risinger , Rolf Hejle Taaning , Vitaly Komnatnyy
IPC分类号: C07C231/02
CPC分类号: C07C231/02
摘要: The present invention relates to a chemical process for the synthesis of the compound 8-[(2-hydroxybenzoyl)amino]octanoic acid or a derivative thereof useful in the process of making sodium 8-[(2-hydroxybenzoyl)amino]octanoate (SNAC), a delivery agent used in solid pharmaceutical compositions. The invention provides an efficient synthesis using less hazardous chemicals and/or a reproducible process that is easier to handle on production scale.
-
-
-
-
-
-
-
-
-